Mechanistically, analyses of tumor tissue and serum samples indicated that RASi reduced AT1R expression in residual bladder cancer cells, thereby suppressing vascular endothelial growth factor (VEGF) secretion [118]. Here, AGTR1 is linked to urinary bladder cancer.